Perceptive Advisors LLC increased its position in shares of Champions Oncology Inc (NASDAQ:CSBR) by 5.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 386,540 shares of the biotechnology company’s stock after acquiring an additional 19,567 shares during the period. Perceptive Advisors LLC owned approximately 3.52% of Champions Oncology worth $1,418,000 as of its most recent filing with the Securities and Exchange Commission.

Separately, GRT Capital Partners L.L.C. increased its holdings in Champions Oncology by 70.6% during the 2nd quarter. GRT Capital Partners L.L.C. now owns 41,064 shares of the biotechnology company’s stock worth $106,000 after acquiring an additional 17,000 shares during the period. 38.04% of the stock is owned by institutional investors.

Separately, ValuEngine lowered shares of Champions Oncology from a “hold” rating to a “sell” rating in a report on Wednesday, December 6th.

Champions Oncology Inc (CSBR) opened at $4.15 on Monday. Champions Oncology Inc has a twelve month low of $2.19 and a twelve month high of $4.79.

Champions Oncology (NASDAQ:CSBR) last issued its quarterly earnings results on Thursday, December 7th. The biotechnology company reported ($0.01) EPS for the quarter. The company had revenue of $5.20 million during the quarter. Champions Oncology had a negative return on equity of 505.60% and a negative net margin of 26.26%.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by Watch List News and is the property of of Watch List News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at https://www.watchlistnews.com/perceptive-advisors-llc-has-1-42-million-position-in-champions-oncology-inc-csbr/1756671.html.

Champions Oncology Profile

Champions Oncology, Inc is engaged in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The Company has two business segments: Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). The POS segment provides physicians and patients information to help guide the development of personalized treatment plans.

Institutional Ownership by Quarter for Champions Oncology (NASDAQ:CSBR)

Receive News & Ratings for Champions Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.